Trial Profile
A Multi-centre, Retrospective Cohort study to evaluate the efficacy and immune-related safety of Nivolumab in patients with Advanced Non-small cell lung cancer: An Open Access Program
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 16 Oct 2019
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Expanded access; Therapeutic Use
- 10 Sep 2019 Results assessing modified prognostic index as a predictor of nivolumab outcomes presented at the 20th World Conference on Lung Cancer.
- 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer
- 18 Jun 2018 New trial record